Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.

The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes

Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.

Provides access to the DOE Genesis Mission Platform, including advanced AI models, AI agents and high-performance computing infrastructure to accelerate future platform development.

LOS ANGELES, CA / ACCESS Newswire / July 23, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, - announced it has been selected to participate in the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together leading researchers, national laboratories and industry leaders to accelerate scientific discovery through artificial intelligence.

As part of the nine-month project, eXoZymes will collaborate with Lawrence Berkeley National Laboratory (LBNL) researchers Dr. Edward Baidoo and Dr. Hector Garcia Martin to develop AI-powered digital twins for cell-free biomanufacturing. The award also provides access to the Genesis Mission Platform, including advanced AI models, AI agents, and high-performance computing resources.